Biohaven的SMA药物试验失败, 库存减少, 而竞争者学者Rock的药物成功, 增加了它的库存。 Biohaven's SMA drug failed trials, dropping its stock, while competitor Scholar Rock's drug succeeded, boosting its stock.

与安慰剂相比,Biohaven的SMA药物daldefgrobep alfa没有显示出运动功能的显著改善,导致其库存下降。 Biohaven's SMA drug taldefgrobep alfa failed to show significant improvements in motor function compared to a placebo, leading to a drop in its stock. 同时,学者Rock's SMA药物Apitegromab在试验中取得成功,其库存增加了33.2%。 Meanwhile, Scholar Rock's SMA drug apitegromab succeeded in trials, boosting its stock by 33.2%. 尽管受到挫折,Biohaven计划探索aldefgrobep alfa在治疗肥胖症方面的潜力,这显示出改变身体构成的前景。 Despite the setback, Biohaven plans to explore taldefgrobep alfa's potential in treating obesity, where it showed promise in changing body composition.